Bifunctional EGFR/CD44-Targeted Diabody-Decorated Doxorubicin-Loaded Solid Lipid Nanoparticles for Targeted Therapy in Triple-Negative Breast Cancer.

Arastehfar M, Soleimani Badie M, Derakhshandeh K

DOI: 10.34172/apb.45929
Published: 2026 Jun
Container: Advanced pharmaceutical bulletin
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.34172/apb.45929,
  title = {Bifunctional EGFR/CD44-Targeted Diabody-Decorated Doxorubicin-Loaded Solid Lipid Nanoparticles for Targeted Therapy in Triple-Negative Breast Cancer.},
  author = {Arastehfar M and Soleimani Badie M and Derakhshandeh K},
  year = {2026},
  journal = {Advanced pharmaceutical bulletin},
  doi = {10.34172/apb.45929},
  url = {https://doi.org/10.34172/apb.45929}
}

RIS

TY  - JOUR
TI  - Bifunctional EGFR/CD44-Targeted Diabody-Decorated Doxorubicin-Loaded Solid Lipid Nanoparticles for Targeted Therapy in Triple-Negative Breast Cancer.
AU  - Arastehfar M
AU  - Soleimani Badie M
AU  - Derakhshandeh K
PY  - 2026
JO  - Advanced pharmaceutical bulletin
DO  - 10.34172/apb.45929
UR  - https://doi.org/10.34172/apb.45929
ER  -

APA

M, A., M, S. B., & K, D. (2026). Bifunctional EGFR/CD44-Targeted Diabody-Decorated Doxorubicin-Loaded Solid Lipid Nanoparticles for Targeted Therapy in Triple-Negative Breast Cancer.. Advanced pharmaceutical bulletin. https://doi.org/10.34172/apb.45929

Source records

pubmed · retrieved 2026-11-10T18:07:29.143Z